Condition or Disorder Intervention vs. Control Outcome Follow-up Duration Event Rates % NNT (95% CI)
CER EER
Acute myocardial infarction1 Angiotensin-converting enzyme (ACE) inhibitors vs. placebo Mortality 30 days 7.6 7.1 210 (125 to 662)
Acute myocardial infarction2 Angiotensin-converting enzyme (ACE) inhibitors vs. placebo Nonfatal heart failure 30 days 15.2 14.6 165 (111 to 488)
Cardiology Chronic heart failure (CHF)3 b-blockers vs. placebo Hospitalisation for CHF 7 months 17 13 24 (16 to 51)
Cardiology Chronic heart failure (CHF)4 b-blockers vs. placebo All-cause mortality 7 months 12 9 40 (24 to 149)
Congestive heart failure5 Spironolactone vs. placebo Mortality 24 months 46 35 9 (7 to 16)
Non-Q-wave coronary events (unstable angina or non-Q-wave MI)6 Enoxaparin vs. unfractionated heparin Composite end point of death, MI or recurrent angina 14 days 19.7 16.6 31 (17 to 191)
Coronary events in healthy persons with low HDL cholesterol levels7 Lovastatin vs. placebo First acute major coronary events and adverse events 5.2 years 6 4 50 (33 to 97)
Cardiovascular events in treated hypertension8 Aspirin vs. placebo Major cardiovascular events 3.8 years 3.9 3.4 176 (90 to 3115)
Myocardial infarction (MI) 1.4 0.9 208 (127 to 551)
Myocardial infarction and average cholesterol levels in older patients9 Pravastatin vs. placebo Major coronary events 5 years 28.1 19.7 11 (8 to 24)
Stroke 7.3 4.5 34 (22 to 333)
Death from coronary artery disease 10.3 5.8 22 (15 to 53)
Coronary artery bypass grafting 11.0 6.6 21 (15 to 56)
Chronic heart failure (CHF)10 Exercise vs. no exercise Death 3.4 years 40.8 18 5 (3 to 21)
All cardiac events 75.5 34 3 (2 to 5)
Hospitalization for CHF 28.6 10 6 (3 to 32)
Severe vasovagal syncope; patients with ≥6 syncopal episodes and a positive tilt-table test result with syncope or presyncope and relative bradycardia11 Pacemaker vs. usual care First recurrence of syncope 2 years 70.4 22.2 3 (1 to 5)
Congestive heart failure12 Home-based intervention vs. usual care Proportion of patients with the combined end point of unplanned readmission or out-of-hospital death 18 months 81.3 67.3 Not significant
Out-of-hospital death 18.8 4.1 7 (3 to 44)
Coronary Heart Disease13 Patients invited to attend nurse led secondary prevention clinics vs. Patients who received regular care Presence, frequency and course of chest pain 12 months 11 7 24 (16 to 170)
Hospital admissions 28 20 13 (9 to 35)
Adults at high risk for cardiovascular events14 Ramipril vs. placebo Myocardial Infarction, stroke and cardiovascular mortality 4 years 18 14 26 (19 to 43)
Patients surviving Myocardial Infarction who had contraindications to b-blockers15 Amiodarone vs. placebo Cardiac mortality 1 year 11 6 23 (12 to 1323)
Arrhythmias 19 8 9 (6 to 16)
Recent-onset atrial fibrillation in patients with or without heart disease16 Oral propafenone vs. placebo Rates of conversion to sinus rhythm at 3 and 8 hours 8 hours 3 hrs: 18 3 hrs: 24 3 hrs: 4 (3 to 6)
8 hrs: 37 8 hrs: 76 8 hrs: 3 (2 to 4)
Patients resuscitated from ventricular arrhythmias; use of implantable cardioverter-defibrillators (ICD) in reducing mortality17 ICD vs. antiarrhythmic drug therapy All-cause mortality 18 months 24 16 13 (8 to 30)
Myocardial infarction with cardiogenic shock18 Immediate revascularization (angioplasty or bypass surgery to be done as soon as possible and within 6 hours of randomization) vs. medical stabilization (intraaortic balloon counterpulsation and thrombolytic therapy with delayed revascularization – minimum 54 hours after randomization) All-cause mortality 6 months 63 50 8 (5 to 66)
Coronary artery disease (CAD) and low levels of high density lipoprotein cholesterol19 Gemfibrozil vs. placebo Nonfatal myocardial infarction or CAD death 5 years 21.7 17.3 23 (13 to 74)
Stroke 6.9 5.1 56 (27 to 725)
Acute myocardial infraction (MI)20 Aspirin and heparin plus angioplasty vs. aspirin and heparin plus streptokinase (control) All-cause mortality 5 years 24 13 10 (6 to 35)
Cardiac mortality 20 7 8 (5 to 15)
Death and nonfatal MI 22 6 6 (4 to 11)
Unstable coronary artery disease21 Dalteparin vs. placebo Death, MI or both at 1 month 6 months 5.8 3.1 37 (23 to 102)
Death, MI or need for revascularization at 3 months 33 29 27 (13 to 208)
Unstable coronary artery disease22 Invasive strategy vs. noninvasive strategy Death, MI or both 6 months 12 9 37 (20 to 398)
Medically refractory angina23 Transmyocardial revascularization (TMR – consisted of a limited muscle-sparingleft thoracotomy and the creation of transmyocardial laser channels) and continued medication vs. continued medication alone Reduction of ≥ 2 angina cases 12 months 11 61 2 (2 to 3)
Congestive heart failure (CHF)24 Usual CHF medicine plus low dose of lisinopril (2.5 or 5.0 mg/d-control) vs. usual CHF medicine plus high dose of lisinopril (30 mg/d) Mortality plus hospitalization 3 years 83.8 79.7 26 (16 to 82)
Mortality plus cardiovascular (CV) hospitalization 74.1 71.1 34 (17 to 264)
Mortality Plus CHF hospitalization 60.4 55.1 17 (12 to 37)
CV mortality plus CV hospitalization 72.7 69.4 30 (16 to 281)
Recent-onset atrial fibrillation25 Oral amiodarone vs. placebo Rates of conversion to sinus rhythm (verified by Holter monitoring) 24 hours 35 87 2 (1 to 4)
Chronic heart failure26 Metroprolol vs. placebo All-cause death or hospital admission 1 year 38 32 17 (12 to 32)
Hospitalization for worsening heart failure 15 10 22 (15 to 39)
Atrial fibrillation (AF)27 Amiodarone (10 mg/kg of body weight) vs. sotalol or propafenone (control) Time to first recurrence of AF confirmed on ECG 468 days 63 35 4 (3 to 6)
Balloon angioplasty28 Routine stent implantation vs. optimal balloon angioplasty with provisional stent Composite end point 6 months 14.9 6.1 11 (7 to 30)
Target vessel Revascularization or surgery 10.1 3.9 16 (9 to 62)
Revascularization or surgery 12.9 5.2 13 (8 to 309)
Unstable coronary artery disease29 Invasive strategy (immediate angioplasty and revascularization) vs. non-invasive strategy Death or myocardial infraction (MI) 1 year 14 10 27 (16 to 92)
Death 3.9 2.2 60 (32 to 306)
Readmission 57 37 5 (4 to 6)
Cardiac intervention after discharge 31 8 5 (4 to 5)
Acute myocardial infarction30 Coronary stenting plus abciximab vs. intravenous alteplase (control) Composite of death, reinfarction or stroke 6 months 23 9 7 (5 to 36)
Angina and percutaneous transluminal coronary angioplasty31 Coumarin and aspirin vs. aspirin alone Composite end point of death, myocardial infarction, target-lesion revascularization and stoke at 30 days 1 year 6.4 3.4 33 (17 to 222)
Composite at 1 year 20 14 17 (10 to 73)
Atrial fibrillation (AF)32 Amiodarone vs. placebo Rates and time to AF or intolerable adverse effects 22 months 88 48 3 (2 to 4)
Sotalol vs. placebo Rates and time to AF or intolerable adverse effects 88 77 Not significant
Patients with cardiovascular disease (CVD) receiving long-term hemodialysis33 Vitamin E vs. placebo CDV events 512 days 34 19 6 (4 to 29)
Myocardial infraction 18 8 10 (5 to 230)
CAD and hypertension34 Acarbose vs placebo Major CV events 3.3 years 4.7 2.2 44 (30 to 436)
Myocardial infaraction35 Warfarin + aspirin, warfarin vs aspirin Composite outcomes 1445 days 15% vs 20%, 17% vs 20% 20 (12 to 51), 30 (16 to 483)
Atrial fibrillation36 Anterior-posterior versus anterior-lateral electrode position Successful cardioversion 24 hours 78 96 6 (4 to 19)
chronic heart failure37 Candesartan 4 or 8 mg vs placebo All-cause mortality 37.7 months 25 23 46 (26 to 463)
acute myocardial infarction38 Coronary angioplasty vs fibrinolytic therapy Composite endpoint 30 day 13.7 8.0 18 (12 to 38)
CAD39 Perindopril vs placebo Large MI or death 4.2 years 9.9 8.0 54 (35 to 115)

References

  1. Circulation 1998; 97:2202-12 
  2. Circulation 1998; 98:1184-91 
  3. N Engl J Med 1999 Sep 2;341(10):709-17 
  4. N Engl J Med 1997 Aug 14;337(7):447-52 
  5. JAMA 1998 May 27;279(20):1615-22 
  6. Lancet 1998 Jun 13;351(9118):1755-62 
  7. Ann Intern Med 1998 Nov 1;129(9):681-9 
  8. Circulation 1999 Mar 9;99(9):1173-82 
  9. J Am Coll Cardiol 1999 Jan;33(1):16-20 
  10. Arch Intern Med 1999 Feb 8;159(3):257-61 
  11. BMJ. 9 May 1998; 316: 1434-7 
  12. N Engl J Med. 20 Jan 2000; 342: 145-53 
  13. J Am Coll Cardiol. 1 Nov 1992; 20: 1056-62 
  14. Ann Intern Med. 15 Apr 1997; 126: 621-5 
  15. N Engl J Med. 27 Nov 1997; 337: 1576-83 
  16. N Engl J Med. 27 Nov 1997; 337: 1576-83 
  17. N Engl J Med. 27 Nov 1997; 337: 1576-83 
  18. N Engl J Med. Aug 26, 1999; 341: 625-34 
  19. N Engl J Med. Aug 5, 1999; 341: 410-8 
  20. N Engl J Med. Nov 4, 1999; 341: 1413-9 
  21. Lancet. Aug 28, 1999; 354: 701-7 
  22. Lancet. Aug 28, 1999; 354: 708-15 
  23. Lancet. Sept 11, 1999; 354: 885-90 
  24. Circulation. Dec 7, 1999; 100: 2312-8 
  25. Am J Cardiol. Feb 15, 2000; 85: 462-5 
  26. JAMA. Mar 8, 2000; 283: 1295-1302 
  27. N Engl J Med. Mar 30, 2000; 342: 913-20 
  28. Lancet. Jun 24, 2000; 355:2199-203 
  29. Lancet. Jul 1, 2000; 356:9-16 
  30. N Engl J Med. Ayg 10, 2000; 343: 385-91 
  31. Circulation. Jul 25 2000; 102: 386-91 
  32. Heart. Sept 2000; 84: 251-7 
  33. Lancet. Oct 7, 2000; 356: 1213-8 
  34. JAMA 2003;5290:486-94 
  35. NEJM 2002;347:969-74.5290:486-9 
  36. Lancet 2002;360:1275-6. 
  37. Lancet 2003;362:759-66. 
  38. N Engl J Med. 2003;349:733-42. 
  39. Lancet. 2003;362:782-8.